Pneumonia after implementation of the pneumococcal conjugate vaccine program in the province of Quebec, Canada

Pediatric Infectious Disease Journal

Volumn 27, Issue 11, 2008, Pages 963-968

  De Wals, Philippe ^a   Robin, Elodie ^b   Fortin, Elise ^c   Thibeault, Roseline ^a   Ouakki, Manale ^c   Douville Fradet, Monique ^c  

^a UNIVERSITÉ LAVAL   (Canada)

^b UNIVERSITÉ RENNES 2   (France)

^c INSTITUT NATIONAL DE SANTÉ PUBLIQUE DU QUÉBEC   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PNEUMOCOCCUS VACCINE; HEPTAVALENT PNEUMOCOCCAL CONJUGATE VACCINE; MENINGOCOCCUS VACCINE; UNCLASSIFIED DRUG;

ARTICLE; CANADA; CHILD; CHILD HOSPITALIZATION; DRUG EFFICACY; EPIDEMIC; FEMALE; HUMAN; INFANT; INTENSIVE CARE UNIT; LENGTH OF STAY; LOBAR PNEUMONIA; LUNG EMPHYSEMA; MAJOR CLINICAL STUDY; MALE; PLEURISY; PNEUMONIA; PRESCHOOL CHILD; PRIORITY JOURNAL; SPRING; BACTERIAL PNEUMONIA; CHI SQUARE DISTRIBUTION; HOSPITALIZATION; NEWBORN; PREVENTIVE HEALTH SERVICE; SEASON; STATISTICAL MODEL; VIRUS PNEUMONIA;

CHI-SQUARE DISTRIBUTION; CHILD, PRESCHOOL; FEMALE; HOSPITALIZATION; HUMANS; IMMUNIZATION PROGRAMS; INFANT; INFANT, NEWBORN; LENGTH OF STAY; LINEAR MODELS; MALE; MENINGOCOCCAL VACCINES; PNEUMOCOCCAL VACCINES; PNEUMONIA, BACTERIAL; PNEUMONIA, VIRAL; QUEBEC; SEASONS;

EID: 58149157956     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e31817cf76f     Document Type: Article

References (20)

1. National Advisosry Committee on Immunization (NACI). Statement on the recommended use of pneumococcal conjugate vaccine. Can Com-mun Dis Rep. 2002;28:1-32.
2. Goldblatt D, Southern J, Ashton L, et al. Immunogenicity and boosting after a reduced number of doses of a pneumococcal conjugate vaccine in infants and toddlers. Pediatr Infect Dis J. 2006;25: 312-319.
3. Whitney CG, Pilishvili T, Farley, et al. Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. Lancet. 2006;368:1495-1502.
4. Quebec Immunization Committee. Assessment of the appropriateness of an immunization program for pneumococcal infections in children using a reduced number of doses of conjugate vaccine. Institut national de santé publique 2005. Available at: http://www.inspq.qc.ca.
5. Tairou F, De Wals P, Bastide A. Validity of death and stillbirth certificates and hospital discharge summaries for the identification of neural tube defects in Quebec City. Chronic Dis Can. 2006;27:120-124.
6. Canuel M, De Serres G, Duval B, Gilca R, De Wals P, Gilca V. Trends in hepatitis A hospitalization and risk factors in Quebec, Canada, between 1990 and 2003. BMC Infect Dis. 2007;7:31.
7. De Wals P, Deceuninck G, Boucher RM, Ouakki M. No increased risk of Guillain-Barre syndrome following administration of serogroup C meningococcal conjugate vaccine in the province of Quebec, Canada. Clin Infect Dis. 2008;46:E75-E77.
8. Guevara RE, Butler JC, Marston BJ, Plouffe JF, File TM, Breiman RF. Accuracy of ICD-9-CM codes in detecting community-acquired pneumococcal pneumonia for incidence and vaccine efficacy studies. Am J Epidemiol. 1999;149:282-289.
9. Boulianne N, De Wals P, Deceuninck G, et al. Impact du programme d'immunisation par le vaccine pneumococcique conjugue heptavelent (VPC-7), au Quebec, Canada. Quebec City: Institut national de sante publique du Quebec; 2007. Available at: http://www.inspq.qc.ca/publications/notice.asp?E= p&NumPublication=681.
10. Davies HD, Wang EE, Manson D, Babyn P, Shuckett B. Reliability of the chest radiograph in the diagnosis of lower respiratory infections in young children. Pediatr Infect Dis J. 1996;15:600-604.
11. Hansen J, Black S, Shinefield H, et al. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than 5 years of age for prevention of pneumonia: updated analysis using World Health Organization standardized interpretation of chest radiographs. Pediatr Infect Dis J. 2006;25:779-781.
12. Dowell SF, Ho MS. Seasonality of infectious diseases and severe acute respiratory syndrome-what we don't know can hurt us. Lancet Infect Dis. 2004;4:704-708.
13. Lucero MG, Dulalia VE, Parreno RN, et al. Pneumococcal conjugate vaccines for preventing vaccine-type invasive pneumococcal disease and pneumonia with consolidation on X-ray in children under two years of age. Cochrane Database Syst Rev. 2004;4:CD004977.
14. Black S, Shinefield H, Fireman B, et al. Efficacy, safety and immuno-genicity of heptavalent pneumococcal conjugate vaccine in chidren. Pediatr Infect Dis J. 2000;19:187-195.
15. Wooten KG, Darling N, Singleton JA, Shefer A. National, state, and local area vaccination coverage among children aged 19-35 months-United States, 2006. MMWR. 2007;56:880-885.
16. Grijalva CG, Nuorti JP, Arbogast PG, Martin SW, Edwards KM, Griffin MR. Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet. 2007;369:1179-1186.
17. Madhi SA, Klugman KP, Vaccine Trialist Group. A role for Streptococcus pneumoniain virus-associated pneumonia. Nat Med. 2004; 10:811-813.
18. National Advisory Committee on Immunization (NACI). Statement on influenza vaccination for the 2004-2005 season. Can Commun Dis Rep. 2004;30:1-3.
19. Smith S, Demicheli V, Di Pietrantonj C, et al. Vaccines for preventing influenza in healthy children. Cochrane Database Syst Rev. 2006;1: CD004879.
20. Hanage WP. Serotype replacement in invasive pneumococcal disease: where do we go from here? J Infect Dis. 2007;196:1282-1284.